Studying the Optimal Intravenous Busulfan Exposure in Pediatric Allogeneic Hematopoietic Cell Transplantation (alloHCT) to Improve Clinical Outcomes: A Multicenter Study  Arief Lalmohamed, PharmD, PhD, Imke Bartelink, PharmD, PhD, Liesbeth van Reij, PharmD, Christopher C. Dvorak, MD, Rada Savic, PhD, Juliëtte Zwaveling, PharmD, PhD, Robbert Bredius, MD, PhD, Antoine Egberts, PharmD, PhD, Marc Bierings, MD, PhD, Morris Kletzel, MD, FAAP, MBA, Peter Shaw, MD, Christa Nath, PhD, Georg Hempel, PhD, Marc Ansari, MD, Maja Krajinovic, MD, PhD, Tayfun Gungor, MD, Robert F. Wynn, MD, Paul Veys, MD, Geoff Cuvelier, MD, Robert Chiesa, MD, PhD, Mary Slatter, MD, Janel Long-Boyle, PharmD, PhD, Jaap Boelens, MD, PhD  Biology of Blood and Marrow Transplantation  Volume 21, Issue 2, Pages S102-S103 (February 2015) DOI: 10.1016/j.bbmt.2014.11.124 Copyright © 2015 Terms and Conditions

Figure 1 Weibull model visualizing the relationship between busulfan exposure and the probability of EFS (highest EFS rates at 75-100mg*h/L, HR = 0.37, 95% CI 0.15-0.92 compared to <50mg*h/L). Biology of Blood and Marrow Transplantation 2015 21, S102-S103DOI: (10.1016/j.bbmt.2014.11.124) Copyright © 2015 Terms and Conditions

Figure 2 Weibull models visualizing the relationship between busulfan exposure and EFS, by underlying disease. Biology of Blood and Marrow Transplantation 2015 21, S102-S103DOI: (10.1016/j.bbmt.2014.11.124) Copyright © 2015 Terms and Conditions